ClinicalTrials.gg
CompletedNCT01879020Updated Jun 17, 2013

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

A Phase 1 interventional study of TA-8995 and TA-8995 in Dyslipidemia, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.

Enrollment
12th of 14
61 · median 116
Started
2009
the only one that year
Phase 1
5 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
2 of 14
Mitsubishi Tanabe Pharma Corporation

Among the 14 studies testing TA-8995 in Dyslipidemias, this one is the 12th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 1, and was the 1st registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About TA-8995

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing TA-8995 in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects

03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • MT-8995
  • Dyslipidemia
  • Cholesteryl ester transfer proteins
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Free from any illness or disease as determined by their medical history, physical examination, laboratory and other tests and as judged by the Investigator.
  • Between 18 - 55 years old.
  • Male of Caucasian ethnic origin.
  • (BMI) in the range of 19 - 33 kg/m² and had a minimum weight of 50 kg. Subjects with a BMI in the range 30.0 - 33.0 kg/m² had to have a waist measurement of ≤ 91 cm.

Exclusion criteria

Exclusion Criteria:

  • High density lipoprotein (HDL)-C level of greater or equal to 2.59 mmol/L (≥ 100 mg/dL) at Screening.
  • Abnormal (ECG) at Screening or Day -1 including a ≥ 430 ms (The QTc-interval was calculated automatically according to Bazett's formula. In the case of results of ≥ 430 ms, QTc was additionally calculated manually using Fridericia's formula which was used as an exclusion criterion).
  • Family history of long QT syndrome, hypokalaemia or Torsades de Pointes
  • Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or history of any psychotic illness
  • Presence or history of gastro-intestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    TA-8995 1 mg

    Drug: TA-8995

  • Experimental
    TA-8995 2.5 mg

    Drug: TA-8995

  • Experimental
    TA-8995 5 mg

    Drug: TA-8995

  • Experimental
    TA-8995 10 mg

    Drug: TA-8995

  • Experimental
    TA-8995 25 mg

    Drug: TA-8995

  • Placebo comparator
    Placebo (TA-8995 1mg)

    Drug: Placebo

  • Placebo comparator
    Placebo (TA-8995 2.5mg)

    Drug: Placebo

  • Placebo comparator
    Placebo (TA-8995 5mg)

    Drug: Placebo

  • Placebo comparator
    Placebo (TA-8995 10mg)

    Drug: Placebo

  • Placebo comparator
    Placebo (TA-8995 25mg)

    Drug: Placebo

Interventions

  • Drug: TA-8995 1mg

  • Drug: TA-8995 2.5mg

  • Drug: TA-8995 5mg

  • Drug: TA-8995 10mg

  • Drug: TA-8995 25mg

  • DrugPlacebo

    Placebo (TA-8995 1mg)

  • DrugPlacebo

    Placebo (TA-8995 2.5mg)

  • DrugPlacebo

    Placebo (TA-8995 5mg)

  • DrugPlacebo

    Placebo (TA-8995 10mg)

  • DrugPlacebo

    Placebo (TA-8995 25mg)

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: 336 hours post dose

  2. Laboratory tests (haematology, biochemistry and urinalysis)

    Time frame: 336 hours post dose

  3. Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)

    Time frame: 336 hours post dose

  4. Area under the plasma concentration (AUC) versus time curve over the final dosing interval (AUC0-τ, Steady-state)

    Time frame: 7 days post the final dose

  5. The last time point 't' with a concentration Ct ≥ Lower limit quantification (LLQ) (AUC0-t, Steady-state)

    Time frame: 7 days post the final dose

Secondary outcomes

  1. Cholesterol ester transfer protein (CETP) activity (%)

    Time frame: 7 days post the final dose

  2. CETP concentration (mg/mL)

    Time frame: 4 hours after the first and the fibal dose

07

Study locations

1 site
  • Momentum Pharma Services GmbH
    Hamburg, 22769, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 17, 2013
Start
Aug 2009
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01879020
Responsible party
Sponsor
First posted
Jun 17, 2013
Start date
Aug 2009
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Jun 17, 2013

Study contacts

Werner Weber, MD
principal investigator · Momentum Pharma Services GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion